

Open camera or QR reader and scan code to access this article and other resources online.



REVIEW ARTICLE

The Biosafety Research Road Map: The Search for Evidence to Support Practices in the Laboratory—*Shigella* spp.

Stuart D. Blacksell^{1,2,*}, Sandhya Dhawan¹, Marina Kusumoto¹, Kim Khanh Le¹, Ben J. Davis¹, Kathrin Summermatter³, Joseph O'Keefe⁴, Joseph Kozlovac⁵, Salama Suhail Almuhairi^{6,†}, Indrawati Sendow⁷, Christina M. Scheel⁸, Anthony Ahumibe⁹, Zibusiso M. Masuku¹⁰, Allan M. Bennett¹¹, Kazunobu Kojima¹², David R. Harper¹³, and Keith Hamilton¹⁴

Abstract

Introduction: *Shigella* bacteria cause shigellosis, a gastrointestinal infection most often acquired from contaminated food or water.

Methods: In this review, the general characteristics of *Shigella* bacteria are described, cases of laboratoryacquired infections (LAIs) are discussed, and evidence gaps in current biosafety practices are identified. **Results:** LAIs are undoubtedly under-reported. Owing to the low infectious dose, rigorous biosafety level 2 practices are required to prevent LAIs resulting from sample manipulation or contact with infected surfaces.

Conclusions: It is recommended that, before laboratory work with *Shigella*, an evidence-based risk assessment be conducted. Particular emphasis should be placed on personal protective equipment, handwashing, and containment practices for procedures that generate aerosols or droplets.

Keywords: *Shigella* spp., pathogen characteristics, biosafety evidence, knowledge gap analysis, disinfection, inactivation

¹Mahidol-Oxford Tropical Research Medicine Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

²Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Nuffield Department of Medicine Research Building, University of Oxford, Oxford, United Kingdom.

⁶Abu Dhabi Agriculture and Food Safety Authority, Abu Dhabi, United Arab Emirates.

© Stuart D. Blacksell et al. 2023; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

³Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

⁴Ministry for Primary Industries, Wellington, New Zealand.

⁵U.S. Department of Agriculture, Agricultural Research Service, Beltsville, Maryland, USA.

⁷Research Center for Veterinary Science, National Research and Innovation Agency, Indonesia.

⁸WHO Collaborating Center for Biosafety and Biosecurity, Office of the Associate Director for Laboratory Science, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

⁹Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria.

¹⁰National Institute for Communicable Diseases of the National Health Laboratory Services, Sandringham, South Africa.

¹¹UK Health Security Agency, Porton Down, United Kingdom.

¹²Department of Epidemic and Pandemic Preparedness and Prevention, World Health Organization, Geneva, Switzerland.

¹³The Royal Institute of International Affairs, London, United Kingdom.

¹⁴World Organisation for Animal Health (OIE), Paris, France.

[†]Current Affiliation: National Emergency Crisis and Disaster Management Authority, Abu Dhabi, United Arab Emirates.

^{*}Address correspondence to: Stuart D. Blacksell, Mahidol-Oxford Tropical Research Medicine Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand, Email: stuart.blacksell@ndm.ox.ac.uk

Introduction

The World Organization for Animal Health, World Health Organization (WHO), and Chatham House are collaborating to improve the sustainable implementation of laboratory biological risk management, particularly in low-resource settings. The Biosafety Research Roadmap project aims to support the application of laboratory biological risk management and improve laboratory sustainability by providing an evidence base for biosafety measures (including engineering controls) and evidence-based biosafety options for low-resource settings. This will inform strategic decisions on global health security and investments in laboratory systems.

This study involves assessing the current evidence base required for implementing laboratory biological risk management, aiming to provide better access to evidence, identifying research and capability gaps that need to be addressed, and providing recommendations on how an evidence-based approach can support biosafety and biosecurity in low-resource settings.

This review describes the general characteristics of *Shigella* spp., and the current biosafety evidence and available information regarding laboratoryacquired infections (LAIs) and laboratory releases are detailed.

Materials and Methods

A 15 member technical working group (TWG) was formed to develop a Biosafety Research Roadmap (BRM) with the goal of supporting the application of laboratory biological risk management and improving laboratory sustainability by providing an evidence base for biosafety measures.

The TWG conducted a gap analysis for a selected list of priority pathogens on procedures related to diagnostic testing and associated research for those pathogens, including but not limited to sample processing, testing, animal models, tissue processing, necropsy, culture, storage, waste disposal and decontamination. To achieve this, the TWG screened databases, websites, publications, reviews, articles, and reference libraries for relevant data. The main research domains used to perform the literature searches were the ABSA database, Belgian Biosafety Server, CDC reports, WHO reports, PubMed, and internet searches for terms related to biosafety matters, including, for example, inactivation, decontamination, laboratory-acquired infections, laboratory releases and modes of transmission. The summary of evidence and potential gaps in biosafety was divided into five main sections: route of inoculation/modes of transmission, infectious dose, laboratory-acquired infections, containment releases, and disinfection and decontamination strategies.

General Characteristics

Shigella spp. are common human enteric bacterial pathogens belonging to the family Enterobacteriaceae. They are gram-negative nonsporulating rod-shaped facultatively anaerobic bacteria. *Shigella* spp. are classified as Risk Group 2 pathogens¹ and are transmitted by the fecal–oral route. Communities lacking public health infrastructure to provide safe drinking water are at the most significant risk for large outbreaks; however, outbreaks related to improperly prepared foods are a global problem. The bacteria demonstrate acid-resistant characteristics, and survival is continued through the digestive system.²

Disease Treatment and Prophylaxis

Shigella infection in young children, the elderly, or the immunocompromised may lead to life-threatening diarrheal disease. The *Shigella flexneri* species causes bacterial dysentery. Treatment of severe *Shigella* spp. related infections include rehydration therapy, and antibiotic therapy using ciprofloxacin and azithromycin,^{3,4} although antimicrobial resistance is a significant issue.⁵ In contrast, a *Shigella* spp. infection in healthy well-nourished individuals is usually self-limiting, and antibiotic treatment is not required. However, after symptoms subside, *Shigella* spp. may be shed in the feces for a month.⁶

Diagnostics

Laboratory procedures commonly used for diagnosing shigellosis are stool sample examination, stool culture, blood culture, polymerase chain reaction, and enzyme-linked immunosorbent assays.⁵ Serological testing of isolated bacteria with antibodies is used to identify the *Shigella* spp.

Biosafety Evidence

Modes of Transmission

Shigellosis is transmitted through the fecal–oral route. Infections are most common in developing country locations where sanitation and hygiene are substandard.⁷ Public health measures are urgently needed to provide uncontaminated water for food preparation and handwashing. *Shigella* is highly transmissible between persons during outbreaks and commonly circulates or clusters in high-risk settings such as day-care centers⁸ and men who have sex with men.⁹ Transmission occurs through contaminated food, water, and fomites with infectious fecal matter.¹⁰

Infectious Dose

The high frequency of initial and secondary transmission is due to the very low infectious dose of *Shigella* spp. between 10 and 200 organisms¹⁰ to 10 and 100 organisms.¹¹

Table 1. Detailed Pathogen	Biosafety Evidence	for Shigella spp.
----------------------------	---------------------------	-------------------

0	vervi	ew o	f t	he	evi	d	ence	and	potenti	al	gaps i	in	bi	osat	ety	1
---	-------	------	-----	----	-----	---	------	-----	---------	----	--------	----	----	------	-----	---

Method	Details	Evidence (direct quote where available)	References	Evidence gap? (yes/no)
Route of inoculation	Fecal–oral route	"Shigella bacteria multiply within colonic epithelial cells, cause cell death and spread laterally to infect and kill adjacent epithelial cells, causing mucosal ulceration, inflammation and bleeding. Transmission usually occurs via contaminated food and water or through person-to-person contact" "Shigella infection can occur by the fecal-oral route of transmission, person-to-person contact or ingestion of contaminated food or water"	26 27	No
Infectious dose	Fecal–oral route Between 10 and 200 pathogenic organisms	 "The number of organisms required to cause the disease is usually 10 to 200 due to the low sensitivity to stomach acid and downregulation of antibacterial proteins of the host by the organism" "A low infective dose, on the order of 10 to 100 organisms is sufficient to produce disease. It is typically transmitted by contaminated food and water or by direct contact with an infected person" 	10	No
LAIs	Two cases, 1981, German laboratory. Infected while processing stool samples	"From another, healthy family member an aerogenic, mannitol negative strain of <i>S. boydii</i> 14 (formerly Sachs A 12) was isolated which subsequently infected a laboratory technician when she was handling the fecal specimen. A second laboratory infection due to this organism occurred while performing the Serény test of pathogenicity. Both persons developed a severe dysenteric syndrome"	21	No
Chemical inactivation	Sonophotocatalytic disinfection	"successfully developed a visible light assisted sonophotocatalysis (SPC) using Fe/ZnO nanoparticles (NPs) for the disinfection of <i>Shigella</i> <i>dysenteriae</i> . A consortia containing <i>S</i> . <i>dysenteriae</i> and <i>S. flexineri</i> was also completely disinfected using SPC. Growth conditions of <i>S. dysenteriae</i> like growth phases and growth temperature had different outcomes on the overall efficacy of SPC"	23	No

(continued)

Table 1. (Continued)

Method	Details	Evidence (direct quote where available)	References	Evidence gap? (yes/no)
	Calcium hypochlorite at 70% active chlorine HTH	 Solution at 0.05%: 7 g or 1/2 tablespoon in 10 L of water. Use for hands, skin clothes Solution at 0.2% 30 g or 2 tablespoons in 10 L of water use for floor, utensils, beds, personal belongings. Solution at 2%: 30 g or 2 tablespoons in 1 L water. Use for excreta, corpses 	6	No
	Ozone treatment	"Treatments with ozone (1.6 and 2.2 ppm) for 1 min decreased <i>S. sonnei</i> population in water by 3.7 and 5.6 log cfu mL(-1), respectively After 5.4 ppm ozone dose, lag-phases were longer for injured cells recovered at 10 degrees C than 37 degrees C. Furthermore, treated cells recovered in nutrient broth at 10 degrees C were unable to grow after 16.5 ppm ozone dose. Finally, after 5 min, <i>S. sonnei</i> counts were reduced by 0.9 and 1.4 log units in those shredded lettuce samples washed with 2 ppm of ozonated water with or without UV-C activation, respectively"	24	No
	Chlorinated lime at 30% active chlorine "bleaching powder"	 Solution at 0.05%: 16 g or 1 tablespoon in 10 L of water. Use for hands, skin, clothes. Solution at 0.2%: 66 g or 4 tablespoons in 10 L of water. Use for floor, utensils, beds, personal belongings. Solution at 2%: 66 g or 4 tablespoons in 1 L of water. Use for excreta, corpses 	6	No
	Sodium hypochlorite at 5% active chlorine "household bleach"	 0.05%: 100 mL or 7 tablespoons in 10 L of water—Use for hands, skin, clothes 0.2%: 450 mL or 30 tablespoons in 10 L of water—Use for floor, utensils, beds, personal belongings 2%: 450 mL or 30 tablespoons in 1 L of water—Use for excreta, corpses 	6	No
Thermal	Autoclave	Standard sterilization cycle of 121°C for 15 min, measured in the most difficult section of the load	6	Yes
	Steam	100°C for 1 h at normal atmospheric pressure	22	Yes

Overview of the evidence and potential gaps in biosafety

HTH, high test hypochlorite; LAIs, laboratory-acquired infections.

Laboratory-Acquired Infections

Shigellosis is one of the most common LAIs. The frequency is likely underestimated due to (1) the selflimiting nature of the infection and (2) the difficulty in pinpointing the source of infection. Although many shigellosis cases in laboratory workers were reported before 1990, fewer cases with incident descriptions and causes can be found in the literature. The most detailed descriptions come from reports of laboratory infections acquired in British clinical laboratories throughout the 1980s.^{12–17} A review of these LAIs shows that most of these occurred while performing routine work, primarily during the manipulation of cultures and secondarily during the manipulation of infected human (serum and stool) specimens.

Inexperience and carelessness were cited as the number one cause of such accidents. It is important to note that manipulations with *Shigella* spp. and other enteric pathogens were performed on the open bench without gloves. Owing to the low infectious dose, trace contamination of the hands may lead to oral inoculation. Since the 1994 study of Walker and Campbell,¹⁸ reported cases of shigellosis LAIs have declined.

Updated evidence-based biosafety guidance for handling *Shigella* and other enteric pathogens now includes full personal protective equipment (PPE) (i.e., laboratory coat, gloves, and eye protection) and a primary barrier (biosafety cabinet or bench shield) to prevent accidental contamination.¹⁹ Handwashing with boiled or disinfected water after glove removal is essential. These factors have likely resulted in decreased shigellosis LAIs over the past decades.

Decontamination and Inactivation

Chemical. It is reported that *Shigella* spp. are susceptible to 1% sodium hypochlorite, 70% ethanol, 2% glutaraldehyde, iodine, phenolics, and formaldehyde; however, only a generic reference^{19,20} has been provided, and there is no clear evidence for the effectiveness of these disinfectants although empirical evidence would suggest that these disinfectants are effective. The WHO provides additional recommendations, with practical advice on preparing appropriate concentrations based on the amount of organic material.²¹

Thermal and autoclaving. Organisms can be heat killed by steaming using an autoclave for 1 h at 100°C under normal atmospheric pressure.²² The autoclave sterilization cycle is very effective, but the time required for steam penetration in a particular load should be validated.

Other methods. Sonophotocatalytic disinfection has been reported effective²³ and 16.5 ppm ozone.²⁴

A complete list of the evidence is provided in Table 1.

Knowledge Gaps

Decontamination and Inactivation

There appears to be a knowledge gap in the literature on the actual effectiveness, especially regarding concentrations and optimal contact times, of common disinfectants such as sodium hypochlorite, ethanol, glutaraldehyde, iodine, phenolics, and formaldehyde.

Laboratory-Acquired Infection

The actual number of *Shigella* spp. LAIs are likely to be under-reported by staff since (1) shigellosis is generally self-limiting and not life threatening, (2) the origin of these infections is not often clear cut, and (3) it may cause embarrassment or fear of sanction. Although this is not strictly a gap, it limits the opportunities to determine the mechanisms and options to prevent LAIs.

Conclusions

According to current guidance, it is recommended that a risk assessment be performed before beginning work with *Shigella* spp.²⁰ Particular emphasis should be placed on PPE, handwashing, manipulation of faucet handles, and decontaminating work surfaces to decrease the risk of LAIs.²⁵ For activities that may produce aerosols or infectious droplets, such as vortexing and pipetting of liquids containing *Shigella* spp., it is recommended that a biological safety cabinet be used.

Centrifugation operations should be performed using rotors with tight-fitting lids or safety cups in the case of bucket rotors.²⁵ Since fewer reports of LAIs have been published formally or anecdotally (as per subject matter experts) most likely because biosafety guidance has relied more strongly on addressing specific risks and evidence collected in prior years, the recommendations described appear appropriate for handling organic materials containing *Shigella* spp.

Acknowledgments

The authors thank Ben Wakefield, The Royal Institute of International Affairs, Chatham House, United Kingdom, for providing administrative support to this project, and David Elliott, United Kingdom International Biosecurity Programme, Defence Science and Technology Laboratory, Porton Down, United Kingdom.

Authors' Disclosure Statement

No competing financial interests exist.

Funding Information

This study was supported by the Weapons Threat Reduction Program of Global Affairs Canada. This research was funded in whole, or in part, by the Wellcome Trust [220211]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

References

- ABSA International. Risk Group Database. 2022. Available from: https:// my.absa.org/tiki-index.php?page=Riskgroups [Last accessed: December 30, 2022].
- Schroeder GN, Hilbi H. Molecular pathogenesis of *Shigella* spp.: Controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev 2008;21(1):134–156; doi: 10.1128/CMR.00032-07
- Tickell KD, Brander RL, Atlas HE, et al. Identification and management of Shigella infection in children with diarrhoea: A systematic review and meta-analysis. Lancet Glob Health 2017;5(12):e1235–e1248; doi: 10.1016/S2214-109X(17)30392-3
- Williams PCM, Berkley JA. Guidelines for the treatment of dysentery (shigellosis): A systematic review of the evidence. Paediatr Int Child Health 2018;38(Suppl. 1):S50–S65; doi: 10.1080/ 20469047.2017.1409454
- 5. Baker S, The HC. Recent insights into *Shigella*. Curr Opin Infect Dis 2018;31(5):449–454; doi: 10.1097/QCO.00000000000475
- 6. World Health Organization. Guidelines for the Control of Shigellosis, Including Epidemics Due to *Shigella Dysenteriae* Type 1. World Health Organization: Geneva; 2005.
- 7. Hale TL, Keusch GT. *Shigella*. In: Medical Microbiology. (th, Baron S. eds.) Galveston: Texas; 1996.
- Arvelo W, Hinkle CJ, Nguyen TA, et al. Transmission risk factors and treatment of pediatric shigellosis during a large daycare centerassociated outbreak of multidrug resistant *Shigella sonnei*: Implications for the management of shigellosis outbreaks among children. Pediatr Infect Dis J 2009;28(11):976–980; doi: 10.1097/INF.0b013e3181a76eab
- 9. Ingle DJ, Easton M, Valcanis M, et al. Co-circulation of multidrug-resistant *Shigella* among men who have sex with men in Australia. Clin Infect Dis 2019;69(9):1535–1544; doi: 10.1093/cid/ciz005
- 10. Aslam A, Okafor CN. Shigella. StatPearls Publishing: Treasure Island, FL; 2020.
- 11. Zaidi MB, Estrada-Garcia T. *Shigella*: A highly virulent and elusive pathogen. Curr Trop Med Rep 2014;1(2):81–87; doi: 10.1007/s40475-014-0019-6
- 12. Grist NR. Infections in British clinical laboratories 1980–81. J Clin Pathol 1983;36(2):121–126; doi: 10.1136/jcp.36.2.121

- Grist NR, Emslie J. Infections in British clinical laboratories, 1982–3. J Clin Pathol 1985;38(7):721–725; doi: 10.1136/jcp.38.7.721
- Grist NR, Emslie JA. Infections in British clinical laboratories, 1984–5. J Clin Pathol 1987;40(8):826–829; doi: 10.1136/jcp.40.8.826
- 15. Grist NR, Emslie JA. Infections in British clinical laboratories, 1986–87. J Clin Pathol 1989;42(7):677–681; doi: 10.1136/jcp.42.7.677
- Grist NR, Emslie JA. Infections in British clinical laboratories, 1988–1989. J Clin Pathol 1991;44(8):667–669; doi: 10.1136/jcp.44.8.667
- Grist NR, Emslie JA. Association of Clinical Pathologists' surveys of infection in British clinical laboratories, 1970–1989. J Clin Pathol 1994;47(5):391–394; doi: 10.1136/jcp.47.5.391
- Walker D, Campbell D. A survey of infections in United Kingdom laboratories, 1994–1995. J Clin Pathol 1999;52(6):415–418; doi: 10.1136/ jcp.52.6.415
- 19. Government of Canada. Pathogen Safety Data Sheets: Infectious Substances—*Shigella* spp. Government of Canada: Canada; 2010.
- World Health Organization. Laboratory Biosafety Manual. WHO: Geneva, Switzerland; 2020.
- Aleksic S, Bockemuhl J, Degner I. Imported shigellosis: Aerogenic Shigella boydii 74 (Sachs A 12) in a traveller followed by two cases of laboratory-associated infections. Tropenmed Parasitol 1981:32(1):61–64.
- Mukhopadhaya A, Mahalanabis D, Khanam J, et al. Protective efficacy of oral immunization with heat-killed *Shigella flexneri* 2a in animal model: Study of cross protection, immune response and antigenic recognition. Vaccine 2003;21(21–22):3043–3050; doi: 10.1016/s0264-410x(03)00111-7
- Rahman APH, Dash S, Mohanty PS, et al. Sonophotocatalytic disinfection of *Shigella* species under visible light irradiation: Insights into its molecular mechanism, antibacterial resistance and biofilm formation. Environ Res 2020;187:109620; doi: 10.1016/j.envres.2020.109620
- Selma MV, Beltran D, Allende A, et al. Elimination by ozone of Shigella sonnei in shredded lettuce and water. Food Microbiol 2007;24(5):492– 499; doi: 10.1016/j.fm.2006.09.005
- U.S. Department of Health and Human Services. Biosafety in Microbiological and Biomedical Laboratories. U.S. Department of Health and Human Services: USA; 2020.
- 26. Niyogi SK. Shigellosis. J Microbiol 2005;43(2):133-143.
- 27. Killackey SA, Sorbara MT, Girardin SE. Cellular aspects of *Shigella* pathogenesis: Focus on the manipulation of host cell processes. Front Cell Infect Microbiol 2016;6:38; doi: 10.3389/fcimb.2016.00038